LifeHealthcare Group (ASX:LHC): Full Year 2017 Results Presentation

Company Presentations


* Continued active surgeon growth
- Additional 14 active surgeons in FY17 bringing total to 137 active surgeons
- 10.5% growth in implants through penetration in complex lower limb orthopaedics, minimally invasive spine and spinal robotics

* Leverage of 3D printed portfolio
- Market leader in 3D printed interbody spine devices, with 197% growth in FY17 and launch of Cascadia 3D printed lateral interbody implants from K2M
- Assisted Australian surgeons to perform 21 patient specific custom procedures for limb salvage in complex lower limb orthopaedics

* Penetration in robotics and imaging
- Three spinal robotic systems installed in FY17 bringing installed base to seven, the largest installation base per capita outside of the United States
- BodyTom interoperative mobile full body CT scanner installed at Epworth and CereTom mobile cranial CT scanner installed in Australia’s first mobile stroke ambulance

* Continued growth in orthopaedics
- Strong growth across complex revision, limb lengthening and limb salvage applications, with particularly strong growth in synthetic biologics offering
- Acquisition of Oceania Orthopaedics on 31 July 2017 strengthens LifeHealthcare’s market position to number two in complex lower limb orthopaedics with a market leading offering in tumour & trauma

* Momentum in biologics
- Continued penetration of synthetic biologics portfolio driving market share gains with Cerapedic’s peptide enhanced bone graft material iFactor across spine and orthopaedics
- Successful launch of allograft biologics in New Zealand, which has a different regulatory approval pathway than Australia

* Performance of acquisitions
- Revenue growth in point of care ultrasound following the acquisition of M4 Healthcare in FY15
- Penetration in interventional cardiology driven by the launch of iFR diagnostic technology and following the acquisition of Medical Vision Australia in FY16